Alamar Biosciences began trading on Nasdaq under ticker ALMR after pricing its initial public offering at $17 per share, raising roughly $220 million in gross proceeds. The proteomics company plans to use the capital to advance development of a clinical version of its Argo HT instrument. In the trading update, Alamar said it intends to file for a U.S. FDA 510(k) submission next year while building its commercial infrastructure and expanding assay content across oncology, cardiology, metabolic disease, and health monitoring. The company also discussed plans for a lower-cost instrument variant designed to broaden installation capacity in smaller labs. Technologically, Alamar bases its assays on NULISA immunoassay arrays that can run on the Argo HT system. The company previously received $10 million from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator to support FDA clearance work. For the biotech supply chain, this IPO highlights renewed capital appetite for lab instrumentation with clear regulatory milestones, not just research-use products.